Study S001447

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Trial of Liraglutide Treatment in Subjects With Newly Diagnosed Type 1 Diabetes.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01879917
Acronym: NewLira
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: TRIPLE
Status: COMPLETED
Enrollment: 65
Start: 2014-02
Primary completion: 2018-08
Lead sponsor: Hvidovre University Hospital
Conditions: Diabetes Mellitus, Type 1
Interventions: DRUG:Liraglutide; DRUG:Placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2012-005317-39; OTHER:U1111-1137-3221

Registered primary outcomes

Beta-cell function [52 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.